This trial enrolled 539 patients with FLT-3 ITD mutated AML and randomized them to 7 + 3 induction followed by high-dose cytarabine consolidation + / − allo-transplant alone or with Quizartinib 40 mg on days 8–21 of induction and daily with consolidation followed by maintenance Quizartinib for up to 3 years. This evidence concerns the gene FLT3 and acute myeloid leukemia.